Gain Therapeutics (GANX) Operating Leases (2020 - 2026)

Gain Therapeutics has reported Operating Leases for 7 years, with the latest figure at $156760.0 in Q2 2026.

• On a quarterly basis, Operating Leases rose 68.83% year-over-year to $156760.0 in Q2 2026; TTM through Jun 2026 was $156760.0, a 68.83% increase from a year earlier, with the FY2025 full-year figure at $211238.0, up 294.12% from the prior year.
• Operating Leases was $156760.0 for Q2 2026 at Gain Therapeutics, down from $182129.0 in the prior quarter.
• The five-year high for Operating Leases was $625449.0 in Q1 2022, with the low at $30589.0 in Q1 2025.
• Average Operating Leases over 5 years is $260818.6, with a median of $220546.5 recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Leases tumbled 91.99% in 2025, then jumped 495.41% in 2026.
• Over 5 years, Operating Leases stood at $441784.0 in 2022, then sank by 47.97% to $229855.0 in 2023, then sank by 76.68% to $53598.0 in 2024, then surged by 294.12% to $211238.0 in 2025, then declined by 25.79% to $156760.0 in 2026.
• The last three Operating Leases figures came in at $156760.0 (Q2 2026), $182129.0 (Q1 2026), and $211238.0 (Q4 2025), per Business Quant data.